2269:HKG
WuXi Biologics (Cayman) Inc
48,20 HK$
arrow_downward
−0,90%(−0,44) 1D
16. okt., 16:08:14 GMT +8 · HKD
search
Vsi simboli
| Simbol | Cena | Sprememba | Odstotna sprememba |
|---|
insights_autoGeneriranje najpomembnejših vpogledov za 2269 …
Odpri
49,98 HK$
Visoka
50,85 HK$
Nizka
45,82 HK$
Tržna kapitalizacija
198,43 mrd.
Povprečni promet
30,42 mio.
Promet
55,18 mio.
Razmerje med ceno delnice in čistim dobičkom
34,48
52-tedenski najvišji tečaj
58,00 HK$
52-tedenski najnižji tečaj
28,48 HK$
Čisti dobiček na delnico
1,40 HK$
Št. izdanih delnic
1,23 mrd.
Št. zaposlenih
15 tis.
Odpri
49,98 HK$
Visoka
50,85 HK$
Nizka
45,82 HK$
Tržna kapitalizacija
198,43 mrd.
Povprečni promet
30,42 mio.
Promet
55,18 mio.
Razmerje med ceno delnice in čistim dobičkom
34,48
52-tedenski najvišji tečaj
58,00 HK$
52-tedenski najnižji tečaj
28,48 HK$
Čisti dobiček na delnico
1,40 HK$
Št. izdanih delnic
1,23 mrd.
Št. zaposlenih
15 tis.
Novice
Iz spletnih virov in novičarskih partnerjev
KITV
·
pred 16 minutami
Nasdaq sinks more than 2% as investors raise questions about AI debt
MarketBeat
·
pred 22 minutami
Liberty Global (NASDAQ:LBTYA) Upgraded to Sell at Wall Street Zen
Simply Wall Street
·
pred 1 uro
What AAON Bears Saw Before The Fall
MarketWatch
·
pred 9 urami
Don’t buy this dip: Several signs suggest there’s more pain ahead for tech stocks
Profil
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
Vizitka: WuXi Biologics (Cayman) Inc
Generalni direktorZhisheng Chen
Št. zaposlenih14,7 tis.
Ustanovljeno2010
Sedež-
Sektor-
Spletno mestowuxibiologics.com